

Amendment to the Claims:

This listing of the claims will replace, without prejudice, all prior versions, and listings, of claims in the application.

1. (currently amended) A monoclonal anti-idiotypic antibody capable of neutralising a human Factor VIII inhibitory antibody, the said inhibitory antibody being directed towards the C2 domain of Factor VIII, characterized by the fact that the complementary determining regions CDR1, CDR2, and CDR3 of the variable heavy chains of said anti-idiotypic antibody have ~~at least 70% sequence identity with the corresponding~~ amino acid sequences depicted in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively and the complementary determining regions CDR1, CDR2, and CDR3 of the variable light chains of said anti-idiotypic antibody have ~~at least 70% sequence identity to the corresponding~~ amino acid sequences depicted in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively.
- 2-17. (cancelled)
18. (previously presented) The monoclonal anti-idiotypic antibody according to claim 1, wherein the variable heavy chain of the said anti-idiotypic antibody is encoded by the nucleotide sequence depicted in SEQ ID NO: 1 or a nucleotide sequence having at least 95% sequence identity to SEQ ID NO: 1 or wherein the variable light chain of

the anti-idiotypic antibody is encoded by the nucleotide sequence depicted in SEQ ID NO: 3 or a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 3.

19. (previously presented) The monoclonal anti-idiotypic antibody according to claim 1, wherein the variable heavy chain of the said anti-idiotypic antibody is encoded by the nucleotide sequence depicted in SEQ ID NO: 1 or a nucleotide sequence having at least 70% sequence identity to SEQ ID NO: 1 and wherein the variable light chain of the anti-idiotypic antibody is encoded by the nucleotide sequence depicted in SEQ ID NO: 3 or a nucleotide sequence having at least 70% sequence identity with SEQ ID NO: 3.
20. (currently amended) The A fragment of the monoclonal anti-idiotypic antibody according to claim 1, which is an  $F(Ab')_2$  fragment, an Fab' fragment, an Fab fragment or a modified version of said  $F(Ab')_2$ , Fab' or Fab fragment.
21. (cancelled)
22. (currently amended) The A monoclonal anti-idiotypic antibody ~~according to claim 1~~ capable of neutralising a human Factor VIII inhibitory antibody, the said inhibitory

antibody being directed towards the C2 domain of Factor VIII, which is the monoclonal antibody Ab14C12 produced by the cell line 14C12 deposited at Belgian Coordinated Collection of Micro-organisms (BCCM) with Accession Number LMBP 5878CB or an antibody fragment derived therefrom, wherein said antibody fragment is capable of neutralizing said inhibitory antibody.

23. (cancelled)
24. (previously presented) A monoclonal cell line expressing a monoclonal anti-idiotypic antibody in accordance with claim 1.
25. (currently amended) ~~The~~A monoclonal cell line, expressing an anti-idiotypic antibody capable of neutralising a human Factor VIII inhibitory antibody, the said inhibitory antibody being directed towards the C2 domain of Factor VIII ~~in accordance with claim 24,~~ which is the cell line 14C12 deposited at BCCM with Accession Number LMBP 5878CB.
26. (previously presented) A pharmaceutical composition comprising a monoclonal anti-idiotypic antibody according to claim 1, in admixture with at least one pharmaceutically acceptable carrier.

27. (withdrawn) A pharmaceutical composition comprising, or an isolated and purified peptide according to claim 23, in admixture with at least one pharmaceutically acceptable carrier.
28. (withdrawn) A method of treatment or prevention of uncontrolled bleeding in a patient with FVIII inhibitory antibodies, said method comprising administering to said patient a therapeutically effective dose of the pharmaceutical composition according to claim 26.
29. (withdrawn) A method of treatment or prevention of uncontrolled bleeding in a patient with FVIII inhibitory antibodies, said method comprising administering to said patient a therapeutically effective dose of the pharmaceutical composition according to claim 27.
30. (withdrawn) A method for developing monoclonal anti-idiotypic antibodies for the manufacture of a medicament against FVIII inhibitors, said method comprising immunizing an animal with inhibitory antibodies directed against the C2 domain of FVIII and screening the immortalized spleen cells of said animal for the production of antibodies which a) neutralise the anti-coagulant activity of FVIII inhibitors for at least 50% and b) do not interact with the binding of FVIII to vWF and phospholipids.

31. (withdrawn) A method for the detection or purification of inhibitory FVIII antibodies from a sample which comprises contacting the sample with the antibodies of claim 1.
32. (previously presented) The monoclonal anti-idiotypic antibody according to claim 1, wherein said anti-idiotypic antibody a) neutralises the anti-coagulant activity of FVIII inhibitors for at least 50% and b) does not interact with the binding of FVIII to vWF and phospholipids.
33. (previously presented) An antigen-binding fragment of the anti-idiotypic monoclonal antibody according to claim 1, capable of neutralizing a human factor VIII inhibitory antibodies.
34. (currently amended) A pharmaceutical composition comprising a monoclonal anti-idiotypic antibody according to claim ~~17~~ 22 , in admixture with at least one pharmaceutically acceptable carrier.
35. (currently amended) A pharmaceutical composition comprising a fragment of the monoclonal anti-idiotypic antibody according to claim 20, in admixture with at least one pharmaceutically acceptable carrier.

36. (previously presented) A pharmaceutical composition comprising an antigen-binding fragment of a monoclonal anti-idiotypic antibody according to claim 33, in admixture with at least one pharmaceutically acceptable carrier.
37. (new) A monoclonal anti-idiotypic antibody according to claim 1 or 22, which is a humanized monoclonal anti-idiotypic antibody.